In a report released today, Clémence Thiers from Stifel Nicolaus maintained a Buy rating on MaaT Pharma (MAAT – Research Report), with a price target of €22.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Clémence Thiers has given his Buy rating due to a combination of factors including MaaT Pharma’s strong financial position and promising clinical developments. The company has extended its cash visibility into the fourth quarter of 2025, thanks to a €13 million private placement, which provides financial stability as it approaches critical milestones.
Additionally, the successful results from the ARES Phase 3 trial for MaaT013 in treating steroid- and ruxolitinib-resistant GI-aGvHD patients have been a significant factor. The trial demonstrated remarkable efficacy, setting the stage for MaaT013 to potentially become a new standard of care. Furthermore, MaaT Pharma is actively pursuing strategic partnerships, particularly in the EU, to leverage its platform’s potential in haemato-oncology, which could enhance its market presence and commercialization efforts.
In another report released on March 19, Kepler Capital also maintained a Buy rating on the stock with a €16.50 price target.